Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT IN TNF PHARMACEUTICALS, INC. (Details Narrative)

v3.24.3
INVESTMENT IN TNF PHARMACEUTICALS, INC. (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
May 20, 2024
Oct. 31, 2024
Oct. 31, 2024
Oct. 31, 2023
May 23, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payment for investment     $ 7,000,000 $ (0)  
Change in fair value of investment Tnf - loss   $ 4,265,000 3,541,000    
TNF Series G Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment owned fair value         $ 17,410,000
TNF Warrants [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment owned fair value         $ 10,986,000
TNF [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment owned fair value   $ 18,799,000 $ 18,799,000    
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payment for investment $ 7,000,000        
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member] | TNF Series G Preferred Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment shares owned 7,000        
Number of common shares issuable upon conversion of preferred stock 3,854,626        
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member] | TNF Warrants [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Investment shares owned 3,854,626